Andrew S Choi, Taylor J Moon, Walid Abuhashim, Anubhuti Bhalotia, Huikang Qian, Kai E Paulsen, Morgan Lorkowski, Crystal Ndamira, Ramamurthy Gopalakrishnan, Animesha Krishnamurthy, William P Schiemann, Efstathios Karathanasis
Targeting ligands have been widely used to increase the intratumoral accumulation of nanoparticles and their uptake by cancer cells. However, these ligands aim at targets that are often also upregulated in inflamed tissues. Here, we assessed the ability of targeted nanoparticles to distinguish metastatic cancer from sites of inflammation. Using common targeting ligands and a 60-nm liposome as a representative nanoparticle, we generated three targeted nanoparticle (NP) variants that targeted either fibronectin, folate, or αv β3 integrin, whose deposition was compared against that of standard untargeted NP...
April 1, 2023: Journal of Controlled Release